Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2003000634) VITAMIN D RECEPTOR ANTAGONISTS AND RELATED COMPOSITIONS AND METHODS OF USE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2003/000634 International Application No.: PCT/US2002/019774
Publication Date: 03.01.2003 International Filing Date: 20.06.2002
Chapter 2 Demand Filed: 14.01.2003
IPC:
C07F 5/02 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
F
ACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
5
Compounds containing elements of the 3rd Group of the Periodic System
02
Boron compounds
Applicants:
BARSONY, Julianna [US/US]; US (UsOnly)
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health Office of Technology Transfer 6011 Executive Boulevard, Suite 325 Rockville, MD 20852, US (AllExceptUS)
Inventors:
BARSONY, Julianna; US
Agent:
LARCHER, Carol ; Leydig, Voit & Mayer, LTD. Two Prudential Plaza Suite 4900 180 North Stetson Chicago, IL 60601-6780, US
Priority Data:
60/299,57020.06.2001US
60/300,40922.06.2001US
Title (EN) VITAMIN D RECEPTOR ANTAGONISTS AND RELATED COMPOSITIONS AND METHODS OF USE
(FR) ANTAGONISTES DES RECEPTEURS DE LA VITAMINE D ET COMPOSITIONS ET METHODES D'UTILISATION ASSOCIEES
Abstract:
(EN) A compound of formula: wherein X is a C2-10 spacer, and R is a substituted or unsubstituted C6-30 aryl, a substituted or unsubstituted C5-30 heteroaryl, or where R'and R' are independently a substituted or unsubstituted aryl or a substituted or unsubstituted alkyl, wherein said compound is a vitamin D receptor (VDR) antagonist, a composition comprising same, and a method of treating a patient for a disease that can be treated prophylactically or therapeutically by administration of a VDR antagonist, which method comprises administering an effective amount of aforementioned compound or composition, whereupon the patient is treated prophylactically or therapeutically for the disease.
(FR) L'invention concerne un composé représenté par la formule générale (I) dans laquelle X représente un espaceur C2-10, et R représente un aryle C6-30 substitué ou non, un hétéroaryle C5-30 substitué ou non ou (II), R' et R'' représentant indépendamment un aryle substitué ou non ou un alkyle substitué ou non. Ce composé est un antagoniste du récepteur de la vitamine D (VDR). L'invention concerne également une composition renfermant ce composé et une méthode destinée au traitement d'un patient atteint d'une maladie pouvant être traitée préventivement ou thérapeutiquement par administration d'un antagoniste du récepteur de la vitamine D. Cette méthode consiste à administrer une dose efficace dudit composé ou de la composition à un patient pour traiter préventivement ou thérapeutiquement la maladie.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)